Fennec Pharmaceuticals (FENC) said Friday that Norgine Pharmaceuticals has commercially launched Pedmarqsi in Germany as part of a licensing deal forged last year between the two companies.
Under the terms of the deal, Fennec said it received an upfront payment of about $43 million and expects to receive up to approximately $230 million in milestone payments along with double-digit tiered royalties on net sales of the chemotherapy side effect treatment starting in the mid-teens and growing to the mid-twenties.
In exchange, Norgine has exclusive licensing rights for the drug, also called sodium thiosulfate, in Europe, Australia, and New Zealand, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.